Drug Library Screen...
 

Drug Library Screen Reveals Benzimidazole Derivatives as Selective Cytotoxic Agents for KRAS-Mutant Lung Cancer  

  RSS

Daniel
(@daniel)
New Member Admin
Joined: 4 years ago
Posts: 331
13/06/2019 11:55 pm  

Fenbendazole is proposed as a relevant drug against KRAS-Mutant Cancer:

"Treatments with two benzimidazole derivatives, methiazole and fenbendazole—both of which are structurally specific—yielded significant suppression of the RAS-related signaling pathways in KRAS-mutated cells. Moreover, combinatorial therapy with methiazole and trametinib, a MEK inhibitor, induced synergistic effects in KRAS-mutant lung cancer cells. Our study demonstrates that these benzimidazole derivatives play an important role in suppressing KRAS-mutant lung cancer cells, thus offering a novel combinatorial therapeutic approach against such cancer cells."

From the following paper published in 2019: https://www.sciencedirect.com/science/article/abs/pii/S030438351930144 2" target="true">Drug Library Screen Reveals Benzimidazole Derivatives as Selective Cytotoxic Agents for KRAS-Mutant Lung Cancer

I also discussed Fenbendazole here: https://www.cancertreatmentsresearch.com/fenbendazole/

Other drugs discussed:

Alexidine dihydrochloride
Thonzonium bromide
Tegaserod maleate
Perhexiline maleate
Quinacrine dihydrochloride hydrate
Auranofin
Methyl benzethonium chloride
Aminacrine
Chlorhexidine
Pyrvinium pamoate
Niclosamide
Terfenadine
Mefloquine hydrochloride
Digoxigenin
Astemizole
Digoxin
Proscillaridin A
Lanatoside C
Digitoxigenin
Benzethonium chloride
Dequalinium dichloride
Fendiline hydrochloride
Thioridazine hydrochloride
Monensin sodium salt
Cycloheximide
Parthenolide
Prenylamine lactate
Albendazole
Fenbendazole
Mebendazole
Verteporfin
Parbendazole
Oxibendazole
Methiazole
Colchicine
Podophyllotoxin
Disulfiram
Hexachlorophene
Clomiphene citrate (Z,E)


Quote
Share: